Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022)
The Korean Society of Radiology and Medical Guidelines Committee amended the existing 2016 guidelines to publish the “Korean Clinical Practice Guidelines for Adverse Reactions to Iodide Contrast for Injection and Gadolinium Contrast for MRI: The Revised Clinical Consensus and Recommendations (202...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Radiology
2022-03-01
|
| Series: | 대한영상의학회지 |
| Subjects: | |
| Online Access: | https://doi.org/10.3348/jksr.2022.0024 |
| _version_ | 1818287299721428992 |
|---|---|
| author | Se Won Oh So Young Park Hwan Seok Yong Young Hun Choi Min Jae Cha Tae Bum Kim Ji Hyang Lee Sae Hoon Kim Jae Hyun Lee Gyu Young Hur Jae Yeon Hwang Sejoong Kim Hyo Sang Kim Ji Young Ryu Miyoung Choi Chi-Hoon Choi |
| author_facet | Se Won Oh So Young Park Hwan Seok Yong Young Hun Choi Min Jae Cha Tae Bum Kim Ji Hyang Lee Sae Hoon Kim Jae Hyun Lee Gyu Young Hur Jae Yeon Hwang Sejoong Kim Hyo Sang Kim Ji Young Ryu Miyoung Choi Chi-Hoon Choi |
| author_sort | Se Won Oh |
| collection | DOAJ |
| description | The Korean Society of Radiology and Medical Guidelines Committee amended the existing 2016
guidelines to publish the “Korean Clinical Practice Guidelines for Adverse Reactions to Iodide Contrast
for Injection and Gadolinium Contrast for MRI: The Revised Clinical Consensus and Recommendations
(2022 Third Edition).” Expert members recommended and approved by the Korean Society of
Radiology, the Korean Academy of Asthma, Allergy and Clinical Immunology, and the Korean Nephrology
Society participated together. According to the expert consensus or systematic literature review,
the description of the autoinjector and connection line for the infection control while using contrast
medium, the acute adverse reaction, and renal toxicity to iodized contrast medium were
modified and added. We would like to introduce the revised contents. |
| first_indexed | 2024-12-13T01:38:17Z |
| format | Article |
| id | doaj.art-a9c0e7847968420a8a70d5a0e4ada24c |
| institution | Directory Open Access Journal |
| issn | 2288-2928 |
| language | English |
| last_indexed | 2024-12-13T01:38:17Z |
| publishDate | 2022-03-01 |
| publisher | The Korean Society of Radiology |
| record_format | Article |
| series | 대한영상의학회지 |
| spelling | doaj.art-a9c0e7847968420a8a70d5a0e4ada24c2022-12-22T00:03:51ZengThe Korean Society of Radiology대한영상의학회지2288-29282022-03-01832254264https://doi.org/10.3348/jksr.2022.0024Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022)Se Won OhSo Young ParkHwan Seok YongYoung Hun ChoiMin Jae ChaTae Bum KimJi Hyang LeeSae Hoon KimJae Hyun LeeGyu Young HurJae Yeon HwangSejoong KimHyo Sang KimJi Young RyuMiyoung ChoiChi-Hoon ChoiThe Korean Society of Radiology and Medical Guidelines Committee amended the existing 2016 guidelines to publish the “Korean Clinical Practice Guidelines for Adverse Reactions to Iodide Contrast for Injection and Gadolinium Contrast for MRI: The Revised Clinical Consensus and Recommendations (2022 Third Edition).” Expert members recommended and approved by the Korean Society of Radiology, the Korean Academy of Asthma, Allergy and Clinical Immunology, and the Korean Nephrology Society participated together. According to the expert consensus or systematic literature review, the description of the autoinjector and connection line for the infection control while using contrast medium, the acute adverse reaction, and renal toxicity to iodized contrast medium were modified and added. We would like to introduce the revised contents.https://doi.org/10.3348/jksr.2022.0024guidelinecontrast mediaiodinemri contrast mediaadverse reactions |
| spellingShingle | Se Won Oh So Young Park Hwan Seok Yong Young Hun Choi Min Jae Cha Tae Bum Kim Ji Hyang Lee Sae Hoon Kim Jae Hyun Lee Gyu Young Hur Jae Yeon Hwang Sejoong Kim Hyo Sang Kim Ji Young Ryu Miyoung Choi Chi-Hoon Choi Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022) 대한영상의학회지 guideline contrast media iodine mri contrast media adverse reactions |
| title | Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022) |
| title_full | Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022) |
| title_fullStr | Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022) |
| title_full_unstemmed | Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022) |
| title_short | Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022) |
| title_sort | korean clinical practice guidelines for adverse reactions to intravenous iodinate and mri gadolinium contrast agents revised clinical consensus and recommendations 3rd edition 2022 |
| topic | guideline contrast media iodine mri contrast media adverse reactions |
| url | https://doi.org/10.3348/jksr.2022.0024 |
| work_keys_str_mv | AT sewonoh koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT soyoungpark koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT hwanseokyong koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT younghunchoi koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT minjaecha koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT taebumkim koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT jihyanglee koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT saehoonkim koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT jaehyunlee koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT gyuyounghur koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT jaeyeonhwang koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT sejoongkim koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT hyosangkim koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT jiyoungryu koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT miyoungchoi koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 AT chihoonchoi koreanclinicalpracticeguidelinesforadversereactionstointravenousiodinateandmrigadoliniumcontrastagentsrevisedclinicalconsensusandrecommendations3rdedition2022 |